Daiichi Sankyo Company, Limited has announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor...
Daiichi Sankyo Company, Limited announced that the FDA has approved Savaysa (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to...
The FDA Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily Savaysa (edoxaban) 60...
Daiichi Sankyo Company, Limited announced that the first patient has been enrolled into the ELIMINATE-AF study. The multinational, randomized phase...